PHVS signals stay bullish as B of A upgrade holds

Three weeks of converging data on PHVS have not reversed. The B of A Securities upgrade to Buy, published October 23, remains the anchor. Options positioning has stayed skewed toward calls, and the borrow market has loosened further since the earlier retail-attention spike.

Why this matters: Pharvaris trades at $31.41, up 13.2% over the past week. The consensus among 11 analysts is Buy, with a mean price target of $51.48. The gap between that target and the current price is wide enough that the analyst alignment alone warrants attention, even before the positioning data.

The upgrade and what sits behind it

B of A analyst Tazeen Ahmad upgraded the stock from Neutral to Buy on October 23, keeping a $44 price target. The stated rationale: deucrictibant's Phase 3 CHAPTER-3 data, which showed an 83% reduction in monthly attack rate versus placebo, and 87% in Type 1 and Type 2 patients. The safety profile has been described as competitive with leading injectables.

That upgrade follows a cluster of target-price increases from September. Morgan Stanley raised its target to $62 from $46. Leerink Partners moved to $65 from $50. RBC Capital went to $62 from $52. Citizens sits at $79. Not one analyst in the current consensus has a Hold or Sell rating.

The bear case has not changed: Pharvaris has no revenue, runs at a net loss, and will need additional capital beyond its $363 million cash position as of the second quarter. The HAE market is crowded, and regulatory and commercial uncertainty remains.

Options positioning

The put-call ratio stood at 1.04 on October 23, against a 20-day mean of 1.65. That is 1.5 standard deviations below the recent average. For context, the PCR ran in a tight band between 1.83 and 1.92 through most of September and early October, then broke lower sharply around October 19 to 20. The ratio briefly touched 0.79 on October 20, the lowest since the 52-week low of 0.0. It has since partially reverted but remains well below its recent baseline.

Borrow market

Availability sits at 2,077% as of October 23, up 75% week-on-week. That is a loose lending market: roughly 14.9 million shares are available against approximately 2.1 million shares short. The cost to borrow spiked to 0.82% on October 22, a 168% jump over the prior week, but has since pulled back to 0.44%. Short interest is 3.2% of free float, down roughly 1.7% over the past week, and broadly flat over the prior month despite the share price move.

The ORTEX short score stands at 38.1 as of October 23, down slightly from 40.3 a week earlier.

Data summary

• Price: $31.41, up 13.2% past week
• Analyst consensus: Buy, 11 Buy / 0 Hold, mean target $51.48
• B of A upgrade: Neutral to Buy, $44 target, October 23
• Put-call ratio: 1.04, 1.5 standard deviations below 20-day mean of 1.65
• Short interest: 3.2% of free float, down 1.7% week-on-week
• Availability: 2,077%, up 75% week-on-week; 14.9 million shares available
• Cost to borrow: 0.44%, down from a weekly peak of 0.82%
• Next earnings: November 12